
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Pediatricians, take note: At its February 22 meeting, The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) made these important recommendations:






